Výsledky vyhledávání

Akademický článek

Tobacco Cessation Motivations, Preferences, and Barriers Among Rural Smokers: Implications for Optimizing Referrals in Clinical Practice

Autor: Kelly A. Hirko, PhD, Patti Moore, RN, Lawrence C. An, MD, Sarah T. Hawley, PhD

Publikováno v: AJPM Focus, Vol 2, Iss 1, Pp 100057- (2023)

Introduction: Rural‒urban smoking disparities have widened in recent years because smoking prevalence reductions have been experienced disproportionately among urban adults. Tobacco cessation programs that work in urban settings may not be reaching

Externí odkaz: https://doaj.org/article/28871f679a0b4d03b777af1e734b4e80

Zobrazit plný text záznamu

An assessment of governance of marine and coastal resources on Koh Tao, Thailand

Autor: Suvaluck Satumanatpan, Hugh Kirkman, Angela Lentisco, Patti Moore

Publikováno v: Ocean & Coastal Management. 148:143-157

This was the first assessment of marine and coastal resource governance on Koh Tao, a small island in the Western Gulf of Thailand. The study assessed perceptions of governance of marine and coastal resources among national and provincial authorities

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca0c2fd779dc8e6a7d1e6dba7d992d06
https://doi.org/10.1016/j.ocecoaman.2017.08.001

Zobrazit plný text záznamu

Partnering for Social Change: Public Health Positively Affecting Physician Practices

Autor: Kim Hodgson, Glenn Brunetti, Lu-Ann Procter, Patti Moore, Pamela Forsyth, Annamaria Feltracco, Sharlene Sedgwick-Walsh, Denise Papaiz

Publikováno v: Social Marketing Quarterly. 7:57-62

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::657dd22de5279bd51a5ff9da4f349e34
https://doi.org/10.1080/15245004.2001.9961165

Zobrazit plný text záznamu

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer

Autor: Corey J. Langer, Patrick Peterson, Mominul Islam, Susan C. Guba, Giorgio V. Scagliotti, Patti Moore, Carla Visseren-Grul, Cesare Gridelli, Thomas Brodowicz

Publikováno v: Clinical lung cancer. 13(5)

A widely held misperception contends that all elderly patients, even those with good performance status (PS 0-1), are unable to tolerate aggressive chemotherapy. The objective of these analyses was to evaluate the survival and safety of treatment wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab0b66c18c278fe82caf1f0c9b3dbdf
https://pubmed.ncbi.nlm.nih.gov/22266043

Zobrazit plný text záznamu

Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer

Autor: Frank V. Fossella, Patrick Peterson, Astra M. Liepa, Patti Moore, José Rodrigues Pereira, Michael C. Perry, Filippo de Marinis, Marc Salzberg, Jacek Jassem, Richard J. Gralla, Martin Reck

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(1)

BackgroundPatients with advanced non-small cell lung cancer (NSCLC) require care that emphasizes symptom palliation in addition to extending survival. The low response rates and minimal survival gains observed in second-line studies underscore the ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed993c421a04b3744f229280ecac6e0
https://pubmed.ncbi.nlm.nih.gov/18166838

Zobrazit plný text záznamu

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis

Autor: Patrick Peterson, Patti Moore, Jean-Louis Pujol, Sofia Paul, Nadia Chouaki, Marc Salzberg, Donald A. Berry

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2(5)

In a recent large phase III study, previously treated patients with advanced non-small cell lung cancer who received pemetrexed demonstrated a survival time similar to patients who received docetaxel (median, 8.3 months with pemetrexed versus 7.9 mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f5bf3733c03a8ddf050f62e70faaab5
https://pubmed.ncbi.nlm.nih.gov/17473654

Zobrazit plný text záznamu